Brind.

Danaher Corporation reported its segment revenues for the Life Sciences, Diagnostics, and Biotechnology divisions on July 22, 2025.

1 report, 1 independent Updated Jul 22

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Danaher Corporation

Keep exploring

The entities involved

Danaher Corporation
American conglomerate
- Sidharth Kapileshwar joins MaxCyte as Chief Corporate Development Officer after leaving Danaher Corporation.Wed 14:03
- MarketBeat listed Danaher, Dexcom, Medtronic, Gilead Sciences, and Boston Scientific as stocks to watch on September 22, 2026.Tue 20:16

Coverage

Newest first; wire copies grouped

Jul 22ZacksDanaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y Danaher Corporation’s DHR second-quarter 2025 adjusted earnings of $1.80 per share beat the Zacks Consensus Estimate of $1.64. The botto